Ron Cohen - Vascular Biogenics Non-Executive Independent Director

VBLTDelisted Stock  USD 0.16  0.01  5.88%   


Dr. Ron Cohen serves as NonExecutive Independent Director at Vascular Biogenics Ltd since February 2015. He is a member of the Audit and Compensation committees. Dr. Cohen work experience includes the following roles Founder, President and Chief Executive Officer at Acorda Therapeutics, Inc, Principal and Officer at Advanced Tissue Sciences, Inc, Director of Dyax Corporation, Director and Chair of the New York Biotechnology Association and Chair of the Board of the Biotechnology Innovation Organization since 2015.
Age 62
Tenure 9 years
Professional MarksPh.D
Phone972 8 993 5000
Cohen holds a Bachelors degree in Psychology from Princeton University and a Doctorate of Medicine degree from Columbia University Vagelos College of Physicians and Surgeons. He completed his residency in Internal Medicine at University of Virginia Medical Center and is Board Certified in Internal Medicine. He is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and was recognized by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry.

Vascular Biogenics Management Efficiency

The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vascular Biogenics until it has trouble settling it off, either with new capital or with free cash flow. So, Vascular Biogenics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vascular Biogenics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vascular to invest in growth at high rates of return. When we think about Vascular Biogenics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives


Geert CauwenberghPhio Pharmaceuticals Corp
Sarah PayneTerns Pharmaceuticals
Jonathan FreemanPhio Pharmaceuticals Corp
Gary BridgerX4 Pharmaceuticals
Angus ForrestTerns Pharmaceuticals
Lindsay RosenwaldAvenue Therapeutics
Rene RussoX4 Pharmaceuticals
Albert SistoTerns Pharmaceuticals
Keith BrownliePhio Pharmaceuticals Corp
Alan HowarthTerns Pharmaceuticals
Isaac BlechX4 Pharmaceuticals
Murray StewartX4 Pharmaceuticals
Paul DormanPhio Pharmaceuticals Corp
David McGirrX4 Pharmaceuticals
Curtis LockshinPhio Pharmaceuticals Corp
Mark TernouthVirax Biolabs Group
Bruce LeithTerns Pharmaceuticals
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Vascular Biogenics (VBLT) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Vascular Biogenics Leadership Team

Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dror Harats, CEO, Director
Amos Ron, CFO
Samuel Backenroth, Chief Officer
Bennett Shapiro, Non-Executive Independent Chairman of the Board
Naamit Sher, VP of Devel. and Regulatory
Ayelet Horn, General Counsel, Company Secretary
Philip Serlin, Non-Executive Independent Director
Dan Gelvan, Non-Executive Independent Director
Eyal Breitbart, Vice President Research
Ron Cohen, Non-Executive Independent Director
Pr MD, CEO Director
Tami MD, VP Devel
Ruth Alon, Non-Executive Independent Director
Erez Feige, Vice President - Business Operations
Ruth Arnon, Non-Executive Independent Director
Yael Cohen, Vice President - Clinical Development
Erez MBA, Sr Operations
Jacob George, Chief Scientific Officer
Jecheskiel Gonczarowski, Non-Executive Independent Director
Deborah Scott, Managing Communications
Jide Zeitlin, Non-Executive Independent Director
Advocate Horn, G Counsel

Vascular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vascular Biogenics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vascular Biogenics' short interest history, or implied volatility extrapolated from Vascular Biogenics options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
FinTech Suite
Use AI to screen and filter profitable investment opportunities